Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Chou, Ai Hsiang ^a   Liu, Chia Chyi ^a   Chang, Jui Yuan ^a   Jiang, Renee ^a   Hsieh, Yi Chin ^a   Tsao, Amanda ^a   Wu, Chien Long ^a   Huang, Ju Lan ^a   Fung, Chang Phone ^b   Hsieh, Szu Min ^c   Wang, Ya Fang ^a   Wang, Jen Ren ^a   Hu, Mei Hua ^a   Chiang, Jen Ron ^d   Su, Ih Jen ^a   Chong, Pele Choi Sing ^a,e  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CENTER FOR DISEASE CONTROL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE; CERCOPITHECUS AETHIOPS; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; FORMALDEHYDE; HUMANS; VACCINES, INACTIVATED; VERO CELLS;

EID: 84894338926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079783     Document Type: Article

References (26)

1. McMinn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26:91-107.
2. Xu J, Qian Y, Wang S, Serrano JMG, LI W, et al. (2010) EV71: An emerging infectious disease vaccine target in the Far East? Vaccine doi:10.1016/j. vaccine.2010.03.003.
3. Lee MS, Chang LY (2010) Development of enterovirus 71 vaccines. Expert Rev Vaccines 9:149-156.
4. Solomon T, Lewthwaite P, Perera D, Cordosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis and control of enterovirus 71. Lancet Infect Dis 10:778-90.
5. Chou AH, Liu CC, Chang CP, Guo MH, Hsieh SY, et al. (2012) Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One 7(4):e34834.
6. Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, et al. (2012) Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, doble-blind, phase 1 clinical trial. Vaccine Doi:10.1016/j.vaccine.2012.03.010.
7. Schmidt NJ, Lennette EH, Ho HH (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129:304-9
8. Brown BA, Pallansch MA (1995) Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 39:195-205.
9. Liu CC, Guo MS, Lin FHY, Hsiao KN, Chang KHW, et al. (2011) Purification and characterization of EV71 viral particles produced from Vero cell grown in a serum-free microcarrier bioreactor system. PLoSONE doi:10.1371/journal.pone. 0020005.
10. Bible JM, Iturriza-Gomara M, Megson B, Brown D, Pantelidis P, et al. (2008) Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J. Clin. Microbiol 46:3192-3200.
11. Chan YF, Sam JC, Abubakar SC (2010) Phylogenetic designation of EV71 genotypes and subgenotypes using complete genome sequences. Infection, Genetics and Evolution 10:404-12.
12. Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, et al. (2009) Reemergence of enterovirus 71 in 2008 in Taiwan: Dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Mincrobiol 47:3653-3662.
13. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2002) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895-904.
14. Liu CC, Lian WC, Butler M, Wu SC (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25:19-24.
15. Tung WS, Bakar SA, Sekawi Z, Rosli R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5:6.
16. Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, et al. (2011) Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 29:4829-38.
17. Dong C, Liu L, Zhao H, Wang J, Liao Y, et al. (2011) Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 29:6269-75.
18. Liu CC, Chang HW, Yang G, Chiang JR, Chow YH, et al. (2011) Development of a quantitative enzyme linked immunosorbent assay for monitoring the EV71 vaccine manufacturing process. J Virol Methods. doi:10.1016/j.jviromet.2011.06. 001.
19. Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al. (2011) Identification and characterization of a cross-neutralization epitope of EV71. Vaccine 29:4362-73.
20. Chang HW, Liu CC, Lin MH, Ho HM, Yang YT, et al. (2011) Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genotype B isolates. J Virol Methods 173:189-95.
21. Chang JY, Chang CP, Tsai HHP, Lee CD, Lian WC, et al. (2012) Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 30:703-711.
22. Chou AH, Liu CC, Chang JY, Lien SP, Guo MH, et al. (2012) Immunological evaluation and comparison of different EV71 vaccine candidates. Clinical and Developmental Immunology Doi:10.1155/2012/831282
23. Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, et al. (2012) Production of EV71 vaccine candidates. Human Vaccines & Immunotherapeutics 8(12):1-9.
24. Cheng A, Fung CF, Liu CC, Lin YT, Tsai HY, et al. (2013) A phase 1, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31:2471-76.
25. Reed LJ, Muench H (1938) A simple method of estimating 50 percent end-points. Am J Hyg 27:493-497
26. Meng FY, Li JX, Li XL, Chu K, Zhang YT, et al. (2012) Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: An open label, phase 1 clinical trial. Hum Vaccin Immunother 8(5):668-674.